tion of chemo-and radiotherapy in a risk-adapted fashion to achieve high cure rates across all stages. Over the last years, the treatment intensity could be markedly reduced [1, 2] to avoid sometimes fatal short-and long-term therapy-related effects such as fatigue, infertility, organ toxicity, or second malignancies. In the case of relapsed or refractory disease (r/r), salvage chemotherapy followed by high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) is performed in eligible patients. In HDCT-ineligible patients or after failure of ASCT, the anti-CD30 antibody-drug conjugate brentuximab vedotin (BV) is approved and leads to high response rates with an acceptable toxicity profile [3] . Nonetheless, a relevant proportion of patients present with refractory, rapidly progressive, or multiply relapsed disease and require further therapy [4] . The anti-programmed death 1 (PD1) checkpoint inhibitors (CIs) nivolumab and pembrolizumab have been investigated in this setting and were recently approved in the US and Europe by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for r/r classical (c)HL. To date, various trials with combinatory regimens and other CIs such as the anti-PD1 antibody REGN2810, the anti-PD1 ligand 1 (PD-L1) antibody avelumab, or the cytotoxic T-lymphocyte-associated protein-4 (CTLA4) inhibitor ipilimumab are ongoing in first-line and r/r cHL, and early results of these trials have recently become available.
Introduction
Hodgkin lymphoma (HL) occurs at a crude incidence of 2.5-3 cases per 100,000 persons per year, and 2,346 new cases of HL in Germany were reported in 2013. As in other industrialized nations, HL develops at all ages with major peaks between 20-30 and 70-80 years of age. At first diagnosis, HL is usually treated with a combina-play a crucial role in self-tolerance [5] [6] [7] . Various malignant tumor cells are able to hijack these pathways by expressing checkpoint molecules or their ligands on their surface, thereby evading effective and durable immune responses [8, 9] . To date, mainly the PD1 axis and the CTLA-4 pathway are targeted by monoclonal antibodies to reverse immune cell anergy and facilitate an effective antitumor immune response. In addition, other pathways and molecules such as lymphocyte activation gene 3 (LAG-3) or killer cell immunoglobulin-like receptor (KIR) are under investigation.
One of the first CIs investigated and approved for advanced melanoma was ipilimumab, a monoclonal antibody targeting CTLA-4, which is expressed on activated T cells. Blockade of its interaction with its ligand B7 on APCs enables co-stimulatory signals facilitating an antitumor response. Nivolumab and pembrolizumab are both antibodies targeting PD1 which blocks the interaction of PD1 on activated T and B cells with its ligands PD-L1 and -L2. Interestingly, PD-L1 is found to a varying extent on the malignant Hodgkin/Reed-Sternberg (HRS) cells in cHL. These drugs thereby also facilitate an effective immune response by bereaving the tumor of its protective niche. Both antibodies are approved in advanced melanoma and non-small cell lung cancer (NSCLC) as well as r/r cHL.
Biology of cHL
In contrast to other malignancies, the tumor in cHL is mainly composed of inflammatory cells providing a protective niche to the sparse CD30-positive malignant HRS cells. cHL hence constitutes a role model for an ineffective anti-tumor immune response, and preclinical data show an important role of the PD1/PD-L pathway in relation to the distinct tumor architecture and HRS cell survival. The cHL microenvironment is heterogeneous, and tumor-infiltrating T cells frequently express PD1 [10, 11] while tumor-infiltrating macrophages were found to express PD-L [12] [13] [14] . As in other malignancies, HRS cells express PD-L1 on their surface to a varying degree [15, 16] , which is either attributed to amplification of the gene locus on chromosome 9p24.1 [15] or Epstein-Barr virus (EBV) infection [16] . The amplification of 9p24.1 is a frequent genetic abnormality in cHL [17] , and besides PD-L expression it also causes Janus kinase 2 (JAK2) protein activity which in a circular fashion again induces PD-L expression by the JAK2/STAT pathway. In addition, other immune escape mechanisms including the CTLA-4 pathway [18] and lack of MHC expression due to beta-2-microglobulin (β2M) deletions have been described in cHL [19, 20] . The β2M alterations raise the question whether a direct T-cell-mediated effect against HRS cells or instead rather an indirect effect by reorganizing the microenvironment mediates the efficacy of CIs in cHL.
Blockade of the PD1/PD-L Axis
Monoclonal antibodies blocking the PD1/PD-L1 interaction are the most intensively studied mode of checkpoint inhibition in cHL. The anti-PD1 antibody nivolumab was first investigated in 23 heavily pretreated patients with r/r cHL and resulted in an overall response rate (ORR) of 87% with an overall survival (OS) of 83% observed at 1.5 years [21] . In the registrational phase II trial, patients with r/r cHL after ASCT were treated in different cohorts according to their BV pretreatment [22] . Across all cohorts (n = 243 patients), an ORR of 69% with a 16% complete response rate (CRR) was observed by centralized review. The CRR was slightly higher in patients without prior BV treatment (29 vs. 13 and 12% for patients with BV after or prior to ASCT, respectively) and was independent of response to prior lines of treatment. The median duration of response was 17 months across all 3 cohorts, with 20 and 13 months in patients achieving a complete response or partial remission, respectively. For all patients, a median progression-free survival (PFS) of 15 months was documented, and the 12-month OS was 92% [23] . Treatment-related adverse events (AEs) grade 3 or 4 were rare with fatigue, diarrhea, rash, infusion-related reactions, and autoimmune hepatitis being the most common (0-1% of patients each). Similar data have been reported for pembrolizumab with an ORR of 65% and a CRR of 16% among 31 extensively pretreated r/r cHL patients. The 24-and 52-week PFS was 69 and 46%, respectively [24] . Within the phase II trial, 210 patients were treated in multiple cohorts according to their prior treatments, including a subgroup without prior ASCT. The ORR was 69% with a CRR of 22.4%. Safety data was comparable to nivolumab, and again no significant differences were observed according to prior treatments or response to last lines of therapy [25, 26] .
Blockade of anti-PD-L1 with the fully human IgG1 monoclonal antibody avelumab was tolerable with °3 treatment-related AEs in 36.7% of patients in a phase I trial. Avelumab resulted in an ORR of 54.8% of r/r cHL patients with a CRR of 6.5%. Among 8 patients treated post allogenic stem cell transplantation (alloSCT), the ORR was 75% with a CRR of 12.5%, suggesting a potentially enhanced graft-versus-lymphoma effect with such agents [27] .
Toxicities associated with CIs are different from those of conventional chemotherapeutic agents and may affect any organ or tissue of the body due to activation of the host immune system. These so-called immune-related AEs (irAE) commonly involve the endocrine glands (adrenal insufficiency, thyroiditis, hypophysitis), skin (vitiligo, rash, pruritus), and gastrointestinal tract (colitis, diarrhea, elevated liver or pancreatic enzymes) [28] . In addition, more rare events such as pneumonitis, cytopenia, or uveitis are reported, and infusion-related reactions occur especially during the first weeks of treatment. Data from cHL trials is limited, and most safety data derives from large randomized trials in advanced-stage melanoma or NSCLC. With anti-PD1 monotherapy, severe irAEs are less frequently observed than with anti-CTLA4 antibodies or double checkpoint inhibition [29, 30] . Skin-related events are seen frequently, while diarrhea, colitis, and hepatic toxicities are less frequently reported, and pneumonitis was observed in < 5% of patients [28, 31, 32] . Most of the irAEs are reversible if recognized early and managed according to well-established organ-specific algorithms. Careful monitoring of patients including laboratory assessments under treatment is hence crucial to allow optimal treatment and prevent irreversible effects. Management of irAEs mostly consists of dose delay and temporary immunosuppression by local or systemic corticosteroids. In severe refractory and potentially life-threatening cases, administration of calcineurin inhibitors, cyclophosphamide, or mycophenolate mofetil is warranted. It is not clear to which extent prophylactic treatment such as corticosteroids can alter treatment efficacy. Administration of rituximab to treat B-cell-mediated thrombocytopenia due to treatment with CIs appeared effective, safe, and without alteration of anti-tumor efficacy in a recent case report [33] .
Due to the mode of irAEs, an alloSCT after anti-PD1 therapy has to be evaluated carefully due to potentially fatal graft-versushost disease (GvHD) [34] . In an early analysis, severe fatal GvHD was documented in 6 of 17 patients treated with alloSCT after nivolumab in phase I/II trials [35] . In patients with administration of nivolumab after alloSCT, acute GvHD predominantly occurred in those with a preexisting history of GvHD, but treatment was generally well tolerated with responses observed [36] . A retrospective analysis of 26 cHL patients treated with nivolumab or pembrolizumab after alloSCT found an ORR of 79% and an OS of 81% with 217 days median follow-up. Severe, mostly hepatic GvHD was observed in 19% of cases with 3 GvHD-related deaths [37] .
To date, the antibodies nivolumab and pembrolizumab are both approved by the FDA and the EMA for r/r cHL. Results of clinical trials investigating antibodies targeting the PD1/PD-L axis are summarized in 
Blockade of the CTLA4/B7 Axis
Administered in 14 patients with r/r cHL after alloSCT, the CTLA4 antibody ipilimumab provided a CRR of 14% and was well tolerated with no cases of relevant GvHD observed [38] . More recently, early results of a phase I/II trial investigating the combination of ipilimumab with BV were reported. Among 18 evaluable patients, an ORR of 72% and a CRR of 50% were observed [39] . Altogether, data regarding the efficacy and safety of ipilimumab monotherapy in cHL is scarce, and ongoing clinical trials are currently further investigating its role (supplementary table, www. karger.com/?DOI=481800).
Combinatory Approaches
Effective anti-tumor immunity depends on various tumor-or host-related factors. The burden of genetic or epigenetic alterations within the tumor and its ability to evade immunity e.g. by altered MHC expression as well as the composition of the microenvironment constitute such factors. Innate and adaptive hostimmunity affecting the priming of an immune response and the phenotyping of effector cells as well as antigenic stimulation and tolerance are additional hallmarks of immune checkpoint blockade [40] . Combinatory approaches either inducing an immunogenic cell death or strengthening the immune response likely work synergistically to enhance the efficacy of CIs. The immunogenic effects of conventional chemotherapy by increasing antigen availability and presentation by APCs have long been recognized also for agents such as cyclophosphamide or anthracyclines which are commonly applied in cHL [41] . Similar preclinical data have been reported for azacytidine, potentially able to enhance the efficacy of CIs by epigenetic priming [42, 43] . For radiotherapy, the local DNA damage initiates an adoptive and innate immune response, leading to distant systemic effects often termed 'abscopal' [44] . Other possibilities to achieve a durable anti-tumor immu- BV = Brentuximab vedotin; q2/3w = every 2/3 weeks; alloSCT = allogenic stem cell transplantation; ORR = overall response rate; CRR = complete response rate; PFS = progression-free survival; OS = overall survival; y = year; m = months; w = weeks; mPFS = median PFS. nity with remission might be the combination of CIs with other targeted agents, virally transduced chimeric antigen receptor (CAR) T cells, directly targeting tumor antigens, or administration of (personalized) anti-tumor vaccines [45, 46] . Figure 1 schematically depicts potential synergies between different treatment modalities. Various clinical trials are currently ongoing to evaluate the efficacy and safety of such combinatory approaches, also in patients with cHL. Early results of 62 patients with r/r cHL treated with BV and nivolumab in a phase I/II study reported an ORR 85% with a 64% CRR and irAEs °3 occurring in < 5% of patients [47] . Similar results were also observed among 19 patients treated with the same combination in another phase I trial (ORR 89%, CRR 50%), with 2 (10.5%) cases of severe pneumonitis observed [48] . In contrast to patients with advanced melanoma, the combination of nivolumab and ipilimumab resulted in similar response rates to nivolumab monotherapy (ORR 74%, CRR 19%) without excess toxicity [49] . Interestingly, a very high CRR of 83.3% (5/6 patients) was reported in cHL patients treated with 5-azacitidine prior to administration of an anti-PD1 antibody, indicating a potential role for sequential therapies with hypomethylating agents [50] .
Perspectives
With the approval for r/r cHL, nivolumab and pembrolizumab have become standard of care in patients with multiply relapsed disease and provide a safe and effective therapy with long-lasting mostly partial remissions. These high ORRs with CIs might be attributable to the PD-L1 expression of HRS cells either caused by amplification of the 9p24.1 locus or due to EBV infection. Nevertheless, responses are also observed in patients without relevant PD-L1 expression, and a direct cytotoxic T-cell effect against HRS cells seems questionable due to the previously described alterations in β2M and MHC class I [19, 20] . A retrospective analysis of r/r cHL patients treated at the University of Cologne identified peripheral leukocyte and eosinophil counts prior to CI treatment as potential predictors for response and PFS [51] . In other malignancies, the PD-L1 status is an important predictor of response, but data in cHL and other entities is inconclusive, likely due to heterogeneous methods and reporting of immunohistochemistry. The mutational load of the tumor was reported as another potential predictor for response since it leads to higher neo-antigen presentation at least in solid tumors [52] . Comprehensive correlative studies on tumor samples and blood taken during the course of therapy are crucial to better understand the mechanisms involved and to refine checkpoint inhibition for patients with cHL.
To date, clinical data is reported for heavily pretreated patients often after ASCT only, and the safety and efficacy of CIs in newly diagnosed likely more immunocompetent patients is unknown. The ongoing randomized phase II NIVAHL trial sponsored by the German Hodgkin Study Group is currently investigating the combination of nivolumab and doxorubicin, vincristine, and dacarbazine (AVD) chemotherapy followed by 30 Gy involved-site radiotherapy ( fig. 2) . In addition to tumor and blood samples, rectal swabs are analyzed to evaluate the microbiome which has been linked to efficacy of immunotherapy [53] . AVD therapy followed by nivolumab is also investigated in patients with high-risk advanced-stage disease or elderly patients in the US. In addition to these chemotherapy-based trials, additional studies investigating combinations of CIs with non-cytotoxic agents and localized radiotherapy are underway. Due to often long-lasting partial remissions, the optimal duration of treatment with anti-PD1 antibodies is still unknown, and many patients remain on therapy due to small positron emission tomography-positive lesions for many months or years. It will be important to develop new response criteria to assess disease status under CIs such as the Response Evaluation Criteria in Solid Tumors (RECIST). Cell-free tumor-associated DNA recently emerged as a potential possibility to monitor disease activity in blood, allowing to measure minimum residual disease also in cHL [54] . These tools should be used to determine the necessity of treatment continuation to limit excessive toxicity and costs associated with prolonged administration of antibodies.
Summary
Checkpoint inhibition with the EMA and FDA approved anti-PD1 antibodies nivolumab and pembrolizumab results in high ORR with durable responses in heavily pretreated r/r cHL patients. In this setting, attentive care of patients treated with CIs is crucial to timely detect irAEs and initiate adequate measures. Currently ongoing trials are investigating other CIs and combinatory approaches in r/r and also first-line treatment of cHL. Correlative studies are crucial to better understand the mechanisms involved and to further refine checkpoint-based therapies in cHL. Carefully designed treatment strategies have the potential to replace the standard of care since they might provide tolerable treatments without conventional side effects and long-term treatment-related morbidity and mortality. Table   Supplementary 
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